Haemonetics Corp. slid after it said quarterly earnings fell 46 percent. The Braintree company, which makes and sells blood-management systems, earned $9.9 million, or 19 cents per share, in the quarter ended in December, compared to $18.3 million, or 36 cents, a year earlier. Administrative and other expenses rose 41 percent; research and development costs rose about 15 percent. Haemonetics said it expects its new OrthoPat Advance system to drive fiscal 2014 growth.
Haemonetics earnings slide 46 percent
You've reached the limit of 10 free articles a month
Stay informed with unlimited access to Boston’s trusted news source.
- High-quality journalism from the region’s largest newsroom
- Convenient access across all of your devices
- Today’s Headlines daily newsletter
- Subscriber-only access to exclusive offers, events, contests, eBooks, and more
- Less than $1 a week